Hypoxic antiblastic stop-flow limb perfusion: Clinical outcome and pharmacokinetic findings of a novel treatment for in transit melanoma metastases

Oncology Reports

Volumn 12, Issue 4, 2004, Pages 895-901

  Pilati, Pierluigi ^a   Mocellin, Simone ^a   Miotto, Diego ^a   Fittà, Claudio ^a   Casara, Dario ^a   Ori, Carlo ^a   Scalerta, Romano ^a   Nitti, Donato ^a   Lise, Mario ^a   Rossi, Carlo Riccardo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Limb perfusion; Melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; MELPHALAN;

AGED; ANOXIA; ARTICLE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIMB; MALE; MELANOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; REGIONAL PERFUSION; SKIN TUMOR; TREATMENT OUTCOME;

AGED; ANOXIA; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE-FREE SURVIVAL; EXTREMITIES; FEMALE; HUMANS; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 16644363050     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, Nova P, Aglione S, Taillibert S and Khayat D: Metastatic melanoma: chemotherapy. Semin Oncol 29: 427-445, 2002. (Pubitemid 35178282)
2. Hsueh EC, Nathanson L, Foshag LJ, Essner R, Nizze JA, Stern SL and Morton DL: Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer 85: 2160-2169, 1999. (Pubitemid 29215555)
3. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhom JH and White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327, 1998. (Pubitemid 28144091)
4. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE and Rosenberg SA: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854, 2002. (Pubitemid 35231542)
5. Rossi CR, Foletto M, Pilati P, Mocellin S and Lise M: Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 29: 400-409, 2002. (Pubitemid 34857888)
6. Vrouenraets BC, Nieweg OE and Kroon BB: Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 83: 1319-1328, 1996. (Pubitemid 26342147)
7. Thompson JF, Hunt JA, Shannon KF and Kam PC: Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 132: 903-907, 1997. (Pubitemid 27344144)
8. Lienard D, Eggermont AM, Kroon BB, Schraffordt Koops H and Lejeune FJ: Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol 14: 202-209, 1998. (Pubitemid 28146511)
9. Rossi C, Mocellin C, Pilati P, Foletto M, Quintieri L, Desalvo G and Lise M: Hyperthermic isolated perfusion with low-dose TNFα and doxorubicin for the treatment of limb threatening soft tissue sarcomas: a phase II study. Ann Surg Oncol (In press).
10. Eggermont AM and ten Hagen TL: Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Curr Oncol Rep 3: 359-367, 2001.
11. Thompson JF and De Wilt JH: Isolated limb perfusion in the management of patients with recurrent limb melanoma: an important but limited role. Ann Surg Oncol 8: 564-565, 2001. (Pubitemid 32735035)
12. Karakousis CP, Kanter PM, Lopez R, Moore R and Holyoke ED: Modes of regional chemotherapy. J Surg Res 26: 134-141, 1979. (Pubitemid 9142155)
13. Karakousis CP, Kanter PM, Park HC, Sharma SD, Moore R and Ewing JH: Tourniquet infusion versus hyperthermic perfusion. Cancer 49: 850-858, 1982. (Pubitemid 12184082)
14. Bland KI, Kimura AK, Brenner DE, Basinger MA, Hirsch M, Hawkins IF Jr, Pierson KK and Copeland EM III: A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg 209: 73-80, 1989. (Pubitemid 19044213)
15. Aigner K and Kaevel K: Pelvic stopflow infusion (PSI) and hypoxic pelvic perfusion (HPP) with mitomycin and melphalan for recurrent rectal cancer. Reg Cancer Treat 7: 6-11, 1994.
16. Aigner KR: Intra-arterial infusion: overview and novel approaches. Semin Surg Oncol 14: 248-253, 1998.
17. Pilati P, Mocellin S, Miotto D, Rossi C, Codello L, Foletto M, Scalerta R, Vieceli G, Ceccherini M, Nitti D and Lise M: Stop-flow technique for loco-regional delivery of antiblastic agents: literature review and personal experience. Eur J Surg Oncol 28: 544, 2002.
18. Thompson JF, Kam PC, Waugh RC and Harman CR: Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 14: 238-247, 1998. (Pubitemid 28146516)
19. Skarsgard LD, Skwarchuk MW, Vinczan A, Kristi J and Chaplin DJ: The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 15: 219-223, 1995.
20. Siemann DW, Chapman M and Beikirch A: Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 20: 287-289, 1991.
21. Taylor YC, Evans JW and Brown JM: Mechanism of sensitization of Chinese hamster ovary cells to melphalan by hypoxic treatment with misonidazole. Cancer Res 43: 3175-3181, 1983. (Pubitemid 13061568)
22. Guadagni S, Santinami M, Patuzzo R, Pilati PL, Miotto D, Deraco M, Rossi CR, Fiorentini G, Di Filippo F, Valenti M and Amicucci G: Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. Melanoma Res 13: 51-58, 2003. (Pubitemid 36269814)
23. Guadagni S, Russo F, Rossi CR, Pilati PL, Miotto D, Fiorentini G, Deraco M, Santinami M, Palumbo G, Valenti M and Amicucci G: Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. Am J Surg 183: 28-36, 2002. (Pubitemid 34178602)
24. Roversi R, Ricci S, Rossi G, Cavallo G, Roversi M and Fiorentini G: Results of flow-controlled antiblastic perfusions (stop-flow technique) earned out with percutaneous technique: 30-month experience. Radiol Med 93: 732-738, 1997.
25. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA and Olthuis GA: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18: 905-910, 1982. (Pubitemid 13147887)
26. Casara D, Rubello D and Pilati P: A simplified procedure for continuous intraoperative external monitoring of systemic leakage during isolated limb perfusion cancer therapy. Tumori 88: S81-S83, 2002.
27. Van Ijken MG, De Bruijn EA, De Boeck G, ten Hagen TL, van der Sijp JR and Eggermont AM: Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. Ann Surg 228: 763-770, 1998. (Pubitemid 30191687)
28. Lindner P, Doubrovsky A, Kam PC and Thompson JF: Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 9: 127-136, 2002. (Pubitemid 34259697)
29. Lienard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, Schmitz P, Clarke J, Steinmann G, Rosenkaimer F and Lejeune FJ: Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 9: 491-502, 1999. (Pubitemid 29494115)
30. Tannock I: Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 62: 1117-1133, 1978.